Inhibitors Clinical Trials

65 recruitingLast updated: May 21, 2026

There are 65 actively recruiting inhibitors clinical trials across 26 countries. Studies span Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3. Top locations include Guangzhou, Guangdong, China, Tianjin, Tianjin Municipality, China, Roma, Italy. Updated daily from ClinicalTrials.gov.


Inhibitors Trials at a Glance

65 actively recruiting trials for inhibitors are listed on ClinicalTrialsFinder across 6 cities in 26 countries. The largest study group is Not Applicable with 14 trials, with the heaviest enrollment activity in Guangzhou, Tianjin, and Roma. Lead sponsors running inhibitors studies include Kong Fanming, Second Xiangya Hospital of Central South University, and Second Affiliated Hospital, School of Medicine, Zhejiang University.

Browse inhibitors trials by phase

About Inhibitors Clinical Trials

Looking for clinical trials for Inhibitors? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Inhibitors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Inhibitors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 65 trials

Recruiting
Phase 2

Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study

Weight GainHealthy VolunteerMetabolic Effects+1 more
National Institute of Allergy and Infectious Diseases (NIAID)120 enrolled1 locationNCT05652478
Recruiting
Not Applicable

Dental Implant Healing With TNF-Alpha Inhibitors

Dental ImplantsEdentulismTNF-alpha Inhibitors
University of Pennsylvania30 enrolled1 locationNCT06538870
Recruiting
Not Applicable

Deprescribing Inappropriate Proton Pump Inhibitors

inappropriate prescribingProton Pump InhibitorsReflux Disease
University of Bern400 enrolled2 locationsNCT06129474
Recruiting
Phase 3

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

Kidney DysfunctionEnd-stage Kidney DiseasePeritoneal Dialysis Complication+2 more
University Health Network, Toronto20 enrolled1 locationNCT05715814
Recruiting

Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors

Lung CancerVenous ThromboembolismArterial Thromboembolism+1 more
Beijing Chao Yang Hospital2,400 enrolled5 locationsNCT06950697
Recruiting

A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCT

Acute LeukemiaMenin InhibitorsPost Hematopoietic Stem Cell Transplantation+4 more
The First Affiliated Hospital of Soochow University20 enrolled1 locationNCT07559695
Recruiting
Phase 3

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Urinary Bladder NeoplasmsImmune Checkpoint InhibitorsMethotrexate+4 more
AstraZeneca150 enrolled59 locationsNCT06960577
Recruiting
Phase 4

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease

AdolescentAlbuminuriaSodium-glucose Co-transporter-2 Inhibitors+1 more
Centenario Hospital Miguel Hidalgo200 enrolled1 locationNCT07405216
Recruiting
Phase 2

Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction

Stomach NeoplasmsImmune Checkpoint Inhibitors
Xijing Hospital116 enrolled5 locationsNCT06576921
Recruiting

A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy

Immune Checkpoint InhibitorsArthritisPolymyalgia Rheumatica
M.D. Anderson Cancer Center20 enrolled1 locationNCT06647134
Recruiting
Phase 3

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

Molecular Mechanisms of Pharmacological ActionPeripheral Nervous System AgentsNeurotransmitter Agents+7 more
Merz North America, Inc.300 enrolled28 locationsNCT07122193
Recruiting

Observational Cohort Study of Chronic Viral Infection in the Central Nervous System

Immune Checkpoint InhibitorsProgressive Multifocal Leukoencephalopathy
Peking Union Medical College Hospital66 enrolled1 locationNCT07512518
Recruiting
Phase 3

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)

Molecular Mechanisms of Pharmacological ActionPeripheral Nervous System AgentsNeurotransmitter Agents+7 more
Merz Aesthetics GmbH300 enrolled26 locationsNCT07210463
Recruiting

Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

COVID19Influenza vaccinationARB+3 more
Consorci Sanitari de Terrassa3,000 enrolled1 locationNCT04367883
Recruiting
Phase 4

PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers

Upper GI BleedingProton Pump Inhibitors
Chinese University of Hong Kong594 enrolled8 locationsNCT05582174
Recruiting
Phase 2

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Non-small Cell Lung CancerImmune Checkpoint Inhibitors (ICIs)
Second Xiangya Hospital of Central South University70 enrolled20 locationsNCT06951646
Recruiting
Phase 4

PCC Treatment for Hemophilia Patients With Inhibitor(2022PCC-A)

HemophiliaInhibitors
Institute of Hematology & Blood Diseases Hospital, China30 enrolled1 locationNCT07406139
Recruiting

Hemophilia A Research Program

PregnancyHemophilia APregnancy Complications+10 more
University of Washington500 enrolled1 locationNCT07414511
Recruiting
Not Applicable

Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)

Arterial Occlusive DiseasesCardiovascular DiseasesCoronary Disease+22 more
Fondazione Ricerca e Innovazione Cardiovascolare ETS576 enrolled1 locationNCT06535568
Recruiting
Not Applicable

Impact of Pilates Exercises on Bone Mineral Density in Breast Cancer Survivors Receiving Hormonal Therapy

Breast CancerBreast Cancer SurvivorsAromatase Inhibitors+2 more
Benha University60 enrolled1 locationNCT07334626